Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Kinross Gold Corporation — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.69 (market cap $6.04B), while Kinross Gold Corporation trades at $23.77 (market cap $27.62B). The key difference: Kinross Gold Corporation is far larger — about 4.6× Iovance Biotherapeutics Inc. Common Stock's market cap, and Kinross Gold Corporation pays a 0.69% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Kinross Gold Corporation for 53 Days on average.
| IOVA | KGC | |
|---|---|---|
Market Cap | $6.04B | $27.62B |
Volume | 14,805,993 | 6,347,266 |
Sector | Health | Basic Materials |
52-Week High | $14.82 | $38.06 |
52-Week Low | $1.81 | $22.47 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $5.97B | $25.70B |
Dividend Yield | — | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Kinross Gold (KGC) trades at $23.82, up 2.76% today, but faces a bearish technical signal despite strong fundamentals. The company reported robust earnings, beating estimates for three consecutive quarters, with 2025 revenue of $7.05 billion and net income of $2.39 billion. However, recent news highlights production guidance cuts and legal investigations, creating mixed sentiment. Valuation ratios appear attractive with a P/E of 8.87 and EV/EBITDA of 4.59, while analyst consensus remains bullish with a $38.80 price target.
The outlook for KGC is cautiously optimistic, driven by strong cash flow and gold price resilience, but near-term risks include operational setbacks and legal overhangs. Investment opportunity lies in its undervaluation and shareholder returns, yet investors must weigh production volatility and cost pressures against fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
